Related Experiment Videos
Baclofen as an adjuvant analgesic for cancer pain
Kinomi Yomiya1, Naoki Matsuo, Shiro Tomiyasu
1Palliative Care Unit, Saitama Cancer Center, Saitama. yomi@cancer-c.pref.saitama.jp
Purpose:
Baclofen is a g-aminobutyric acid receptor agonist commonly used for managing many types of neuropathic pain. The effect of baclofen on cancer pain has not previously been studied. This retrospective study evaluated the efficacy of baclofen in patients with cancer pain.
Methods:
We reviewed the medical records of all patients given baclofen orally as an analgesic for cancer at 5 institutions.
Result:
Twenty-five patients received 10 to 40 mg of baclofen for cancer pain relief. Twenty patients have undergone neuropathic pain such as paroxysmal or lancing, sharp, or like an electric shock. Baclofen was effective in 21 of 25 patients and significantly reduced Numeric Rating Scale (pain score, 0-10; P < .0001). Nine patients reported mild adverse events: none of these 9 patients had to discontinue baclofen due to adverse events.
Conclusion:
Our findings suggest that baclofen may be a useful adjuvant analgesic in the treatment of cancer pain.
Related Concept Videos
Analgesia and Pain Management
Skeletal Muscle Relaxants: Therapeutic Uses
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Opioid Analgesics: Synthetic and Semisynthetic Opioids